Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients (NCT07523334) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients
China120 participantsStarted 2026-04
Plain-language summary
Esketamine is frequently used during the perioperative period for supplemental analgesia. Small sample size trials showed that subanesthetic dose esketamine may decrease postoperative neurocognitive complications. However, conflicting results exist and optimal dose of esketamine remains to be determined. This dose-exploring pilot trial is designed to evaluate the safety and efficacy of three different perioperative esketamine dosing regimens in older patients undergoing major non-cardiac surgery. The primary purpose is to explore the optimal dosing strategy that produce maximal neurocognitive benefits with minimal adverse neuropsychiatric symptoms.
Who can participate
Age range65 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged \>=65 but \<= 90 years;
✓. Scheduled to undergo non-cardiac surgery with an expected duration of \>= 2 hours under general anesthesia;
✓. Requiring patient-controlled intravenous analgesia (PCIA) after surgery.
Exclusion criteria
✕. Unable to communicate preoperatively due to visual or auditory impairment, language barrier, or severe dementia;
✕. Comorbid with schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;
✕. Traumatic brain injury or neurosurgery;
✕. Severe hepatic dysfunction (Child-Pugh Class C), severe renal dysfunction (receiving dialysis preoperatively), or American Society of Anesthesiologists physical status classification \>= Ⅳ;
✕. Expected admission to the Intensive Care Unit with endotracheal intubation after surgery;